Jeremy Pitts has been named the inaugural Houston managing director for Activate. Photo via LinkedIn

An organization that promotes early-stage innovation within the hardtech space has named one of the founding entrepreneurs of Greentown Labs as its local Houston lead.

Activate named Jeremy Pitts as the Houston managing director this month. The nonprofit, which announced its new Houston program earlier this year, was founded in Berkeley, California, in 2015 to bridge the gap between the federal and public sectors to deploy capital and resources into the innovators creating transformative products.

For Activate Houston, the challenge is to focus on finding and supporting innovators within the energy sector.

"There are so many reasons to be excited about the energy transition and overall innovation ecosystem in Houston — the region's leadership in energy and desire to maintain that leadership through the energy transition, the many corporations leading the charge to be part of that change who are speaking with their actions and not just their words, the incredible access to talent, the region's diversity, the list goes on and on," Pitts tells InnovationMap.

"Houston is second to none when it comes to solving hard problems and is a region that knows how to build things and execute on projects at the scale needed to tackle the energy transition," he continues.

Pitts was one of the founders of Greentown Labs, and served in a leadership role for the organization between 2011 and 2015. He moved to Houston from Ohio to take the position, but has previously worked in the Bayou City's energy sector.

"Jeremy is the ideal inaugural managing director for Houston — having built a startup there, co-founding the Greentown Labs community, and demonstrating a strong track record of thoughtful mentorship," Aimee Rose, executive managing director of Activate, tells InnovationMap. "Jeremy will serve as the primary guide for our Houston fellows, helping them navigate the ups and downs facing first-time technical founders, and create and foster community among them. He will also plug Activate into the ecosystem to serve as a synergistic partner to all the other amazing initiatives across Texas."

The program finds local and regional early-stage founders — who have raised less than $2 million in funding — who are working on high-impact technology. Each cohort consists of 10 fellows that join the program for two years. The fellows receive a living stipend, connections from Activate's robust network of mentors, and access to a curriculum specific to the program.

Applications for the inaugural Houston cohort for 2024 will open September 15 and will close sometime in October.

Since its inception, Activate has supported 104 companies and around 146 entrepreneurs associated with those companies. With the addition of Houston, Activate will be able to back 50 individuals a year.

"As an impact-focused organization that focuses on turning talented scientists and technology leaders into product and business leaders, Activate enters the Houston ecosystem with no ulterior motives other than finding the right partners and being part of a community that enables scientists to solve hard problems and help make the world a better place," Pitts says. "I have a deep appreciation for all that Houston can offer having started and run a startup here previously and having experience in both traditional energy and climate tech."

Tomorrow, the organization is hosting a virtual event to introduce Pitts and the program to the Houston innovation ecosystem. Those interested in learning more can attend the event or find more information online.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.